Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FFCD 1703 - POCHI
2019-002407-18Phase 2Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Progression-free survival at 10 months. Started Jan 2020; status: active.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2019-002407-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002407-18.